Kidney and Cardiovascular Effectiveness of Empagliflozin Compared With Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes-Reference-Cited by-同舟云学术

Kidney and Cardiovascular Effectiveness of Empagliflozin Compared With Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes

Published:2024-06 Issue: Volume:221 Page:52-63
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Edmonston Daniel^ORCID,Mulder Hillary,Lydon Elizabeth,Chiswell Karen,Lampron Zachary,Shay Christina,Marsolo Keith,Jones William Schuyler,Butler Javed,Shah Raj C.,Chamberlain Alanna M.,Ford Daniel E.,Gordon Howard S.,Hwang Wenke,Chang Alexander,Rao Ajaykumar,Bosworth Hayden B.,Pagidipati Neha

Funder

Boehringer Ingelheim Corp USA

Publisher

Elsevier BV

Reference34 articles.

1. Centers for Disease Control and Prevention. National diabetes statistics report. Available at: https://www.cdc.gov/diabetes/data/statistics-report/index.html. Accessed on March 13, 2024.

2. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007–2012;Wu;BMJ Open Diabetes Res Care,2016

3. Kidney disease and increased mortality risk in type 2 diabetes;Afkarian;J Am Soc Nephrol,2013

4. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy;Perkovic;N Engl J Med,2019

5. Dapagliflozin in patients with chronic kidney disease;Heerspink;N Engl J Med,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular and Renal Benefit of Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes;The American Journal of Cardiology;2024-07